Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in cameroon

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Bekolo, Cavin E ^a   Sonkoue, Cecile ^b   Djidjou, Hortense ^b   Bekoule, Patrick S ^b   Kollo, Basile ^c  

^a Centre Médical d'Arrondissement de Baré   (Cameroon)

^b Regional Hospital of Nkongsamba   (Cameroon)

^c UNIVERSITY OF DOUALA   (Cameroon)

Author keywords

Antiretroviral therapy; Cameroon; HIV; Laboratory monitoring

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; EFAVIRENZ; GLUCOSE; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CAMEROON; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; ERYTHROCYTE VOLUME; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HEMATOLOGY ANALYZER; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT MONITORING; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; CHEMICALLY INDUCED; DRUG-INDUCED LIVER INJURY; EARLY DIAGNOSIS; EVALUATION STUDY; HIV INFECTIONS;

ADULT; ANEMIA; ANTI-HIV AGENTS; CAMEROON; DRUG-INDUCED LIVER INJURY; EARLY DIAGNOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; STAVUDINE; ZIDOVUDINE;

EID: 84908460206     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-519     Document Type: Article

References (27)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 2013, Geneva: UNAIDS, Joint United Nations Programme on HIV/AIDS (UNAIDS).
2. World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach 2013, Geneva: World Health Organization 2013, World Health Organization.
3. National Institute of Statistics Enquête Démographique et de Santé et à Indicateurs Multiples EDS-MICS 2011 2011, Yaounde: National Institute of Statistics, National Institute of Statistics.
4. Ministere de la Sante Publique du Cameroun Rapport annuel des activités de lutte contre le VIH et les IST au Cameroun 2011, Yaounde: Ministere de la Sante Publique du Cameroun, Ministere de la Sante Publique du Cameroun.
5. Ministere de la Sante Publique du Cameroun Directives nationales de prise en charge par les antirétroviraux des personnes (Adultes et Adolescents) infectées par le VIH 2010, Yaounde: Ministere de la Sante Publique du Cameroun, Ministere de la Sante Publique du Cameroun.
6. Kalyesubula R, Kagimu M, Opio K, Kiguba R, Semitala C, Schlech W, Katabira E. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci 2011, 11(1):16-23. 3092323, 21572852.
7. Bekolo CE, Webster J, Batenganya M, Sume GE, Kollo B. Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon. BMC Res Notes 2013, 6:512. 10.1186/1756-0500-6-512, 3937159, 24308609.
8. Koenig SP, Schackman BR, Riviere C, Leger P, Charles M, Severe P, Lastimoso C, Colucci N, Pape JW, Fitzgerald DW. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis 2010, 51(5):600-608. 10.1086/655762, 3010921, 20649436.
9. Central Bureau of the Census and Population Studies La population du Cameroun en 2010 2010, Yaounde: Central Bureau of the Census and Population Studies, Central Bureau of the Census and Population Studies.
10. Pollard R, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20:1071-1092. 10.1016/S0149-2918(98)80105-7, 9916603.
11. Martinez E, Blanco J, Arnaiz J. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS (London, England) 2001, 15:1261-1268.
12. Stern J, Robinson P, Love J, Lanes S, Imperiale M, Mayers D. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S21-S33.
13. Wit F, Weverling G, Jurriaans S, Lange J. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31. 10.1086/341084, 12089658.
14. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007, 45(8):1093-1101. 10.1086/521150, 17879931.
15. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD, Pape JW, Fitzgerald DW. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353(22):2325-2334. 10.1056/NEJMoa051908, 16319381.
16. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004, 37(5):1566-1569. 10.1097/00126334-200412150-00005, 15577409.
17. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004, 87(7):760-767.
18. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006, 52(4):244-248.
19. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005, 10(5):615-624.
20. Idoko J, Akinsete L, Abalaka A. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med 2002, 52:83-86.
21. Ibeh BO, Omodamiro OD, Ibeh U, Habu JB. Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria. J Biomed Sci 2013, 20:73. 10.1186/1423-0127-20-73, 3851766, 24099597.
22. Owiredu WK, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci 2011, 11(1):2-15. 3092327, 21572851.
23. Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, Boulle A, Wehbe F, Masys D, Iriondo-Perez J, Hemingway-Foday J, Law M, . Western Africa, Eastern Africa, Southern Africa, Caribbean and Central and South America, and Asia Pacific Regions of the International Epidemiologic Databases to Evaluate AIDS-IeDEA Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc 2012, 15(1):5. 10.1186/1758-2652-15-5, 3292983, 22289654, Western Africa, Eastern Africa, Southern Africa, Caribbean and Central and South America, and Asia Pacific Regions of the International Epidemiologic Databases to Evaluate AIDS-IeDEA.
24. Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, Chilongola J. The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci 2012, 12(1):2-7. 3462512, 23066413.
25. Johannessen A, Naman E, Gundersen SG, Bruun JN. Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis 2011, 11:190. 10.1186/1471-2334-11-190, 3145581, 21745396.
26. Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc 2010, 13:42. 10.1186/1758-2652-13-42, 2991285, 21047391.
27. Tokponnon F, Ogouyémi A, Sissinto Y, Sovi A, Gnanguenon V, Cornélie S, Adéothy A, Ossè R, Wakpo A, Gbénou D, Oke M, Kinde-Gazard D, Kleinschmidt I, Akogbeto MC, Massougbodji A. Impact of long-lasting, insecticidal nets on anaemia and prevalence of Plasmodium falciparum among children under five years in areas with highly resistant malaria vectors. Malar J 2014, 13(1):76. 10.1186/1475-2875-13-76, 3973997, 24581394.